Our Work

Our survey of 190 U.S. endocrinologists finds GLP-1 and SGLT2 prescribing at 90%+ and rising, while many patients resist starting basal insulin.

dQ&A data show that users' perceptions of an algorithm's aggressiveness strongly impact satisfaction and NPS.

Our research reveals low awareness of DKA and ketone testing among type 2 diabetes patients on SGLT2 inhibitors, highlighting urgent education needs.